Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
08
2022
accepted:
25
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.
Identifiants
pubmed: 36389397
doi: 10.1155/2022/7251658
pmc: PMC9649302
doi:
Types de publication
Case Reports
Langues
eng
Pagination
7251658Informations de copyright
Copyright © 2022 Christos Fokoloros et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87
pubmed: 30416055
J Allergy Clin Immunol. 2009 Nov;124(5):1047-54
pubmed: 19895993
J Clin Pathol. 2006 Mar;59(3):298-302
pubmed: 16505282
Leuk Res. 2005 Oct;29(10):1227-32
pubmed: 16111540
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Leukemia. 2011 Jun;25(6):1050-3
pubmed: 21445078